9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

US12060357B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Matthew A. Larsen · Dedham, US
• Amjad Ali · Freehold, US
• Jared N. Cumming · Garwood, US
• Duane DeMong · Somerville, US
• Qiaolin Deng · Edison, US
• Thomas H. Graham · Somerville, US
• Elisabeth Hennessy · Weston, US
• Andrew J. Hoover · Boston, US
• Ping Liu · Shanghai, CN
• Kun Liu · Edison, US
• Umar Faruk Mansoor · Framingham, US
• Jianping Pan · Monmouth Junction, US
• Christopher W. Plummer · Hoboken, US
• Aaron Sather · Melrose, US
• Uma Swaminathan · Riverview, US
• Huijun Wang · Westfield, US
• Yonglian Zhang · Metuchen, US

Key dates

• Filing date: Mar 31, 2022
• Grant date: Aug 13, 2024
• Expiry date: Mar 31, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.